HANX is making waves in women’s health with the introduction of revolutionary weight loss injections, designed to help women feel empowered, confident, and sexy in their own skin.
HANX, a UK-based women’s health brand, is expanding into weight management with the launch of GLP-1 medications—Mounjaro (tirzepatide) and Wegovy (semaglutide). Known for its intimate care products, HANX is now broadening its offerings to address the weight management needs of women, especially those with conditions like Polycystic Ovary Syndrome (PCOS), endometriosis, and menopause.
These medications work by reducing cravings, lowering blood sugar levels, and slowing gastric emptying, helping patients feel fuller longer. Dr. Sarah Welsh, Co-Founder of HANX, notes that many women find lifestyle changes alone insufficient for weight loss, particularly during menopause or when dealing with conditions like PCOS. “By offering medications alongside educational resources, we aim to provide effective support for women’s weight management,” she says.
The new Weight Management Programme includes a digital health consultation, a prescription for Mounjaro or Wegovy if suitable, and access to resources like calorie-controlled recipes and exercise plans. Patients also receive monthly check-ins to track progress and ensure long-term success.
HANX Co-Founder and CEO Farah Kabir sees this as a natural extension of the brand’s mission to provide comprehensive women’s health solutions. “Weight impacts many aspects of women’s health, and we’re excited to offer these tools to help our community manage their health more effectively,” she states.
The program, starting at £185, complements HANX’s existing services, which include intimate care products and digital pharmacy offerings. With this new launch, HANX continues to expand its role as a leader in the Femtech space, providing innovative solutions for women’s health needs at every stage of life.
For more information, visit the HANX website.
